Valley health experts answer COVID-19 vaccine questions in ABC15 town hall
Health experts are answering your questions Tuesday.
and last updated 2020-12-15 21:05:58-05
PHOENIX â The first doses of Pfizer s COVID-19 vaccine arrived in Arizona Monday, with the state expecting to have around 58,500 doses split between Maricopa and Pima counties first.
That arrival will be followed by several more shipments of the vaccine from Pfizer and Moderna coming in through the next week.
As our state starts to receive the much-anticipated vaccine, we know Arizona residents still have questions over safety, how the vaccine will be rolled out, and when can the general public really expect to receive it.
The work could lead to new immunotherapy treatments.
The immune system fights bacteria, viruses, and other pathogens by utilizing several types of T cells, all of which have receptors that are specific to particular antigens. On killer T cells, the receptor works in concert with three signaling modules and a coreceptor to destroy the infected cell.
“When we saw that the 5MCAR T cells completely eliminated the harmful T cells that invaded the pancreas, we were blown away.”
The researchers copied the evolutionary design to engineer a five-module chimeric antigen receptor, or 5MCAR, T cell.
“The 5MCAR was an attempt to figure out if we could build something by biomimicry, using some of evolution’s natural pieces, and redirect T cells to do what we want them to do. We engineered a 5MCAR that would direct killer T cells to target autoimmune T cells that mediate type 1 diabetes,” says Michael Kuhns, an associate professor in the immunobiology department at the University of A
Applications to medical school up amid COVID-19 pandemic
More people are applying to medical schools amid COVID-19 pandemic
Officials with University of Arizona s College of Medicine say they have 7,000 applications this year for 120 slots.
PHOENIX - As COVID-19 continues to spread in Arizona and elsewhere, applications to medical school are at an all-time high.
From a young age, Jon Kelley had a passion for medicine, as well as music. When the music stopped, his drumbeat took him to med school. Now, Dr. Kelley is a second-year resident during the ongoing COVID-19 pandemic.
Dr. Kelly said didn’t think of COVID when he thought of getting into medicine.
Hits: 845
TUCSON, AZ, USA I December 8, 2020 I Procyon Technologies LLC today announced that it has entered into an exclusive research collaboration and license agreement with Novo Nordisk A/S to develop an implantable cell encapsulation device to be used in Novo Nordisk s development of a novel therapy for Type 1 diabetes.
The collaboration brings together Procyon Technologies expertise with development of oxygen enabled implantable cell encapsulation devices and Novo Nordisk s expertise in stem cell-derived insulin-secreting cells.
The partners will work together to further optimize the device and cells for clinical testing and accelerate the path to First Human Dose with the joint vision of delivering a functional cure for people living with Type 1 diabetes.